Cytokinetics Q3 EPS $(1.35) Misses $(0.74) Estimate, Sales $378.00K May Not Compare To $20.24M Estimate
Portfolio Pulse from Benzinga Newsdesk
Cytokinetics (NASDAQ:CYTK) reported Q3 losses of $(1.35) per share, missing the analyst consensus estimate of $(0.74) by 82.43%. This is an 11.18% increase over losses from the same period last year. The company also reported quarterly sales of $378.00K, missing the analyst consensus estimate of $20.24M by 98.13%, a decrease of 84.97% over sales from the same period last year.
November 02, 2023 | 8:01 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Cytokinetics reported a larger than expected loss and significantly lower sales than estimated for Q3. This could negatively impact the stock in the short term.
Cytokinetics reported a larger than expected loss for Q3, missing the analyst consensus estimate by 82.43%. Additionally, their sales were significantly lower than estimated, missing the consensus by 98.13%. This poor financial performance is likely to negatively impact investor sentiment and could lead to a decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 100
RELEVANCE 100